Supplementary Table 2.
Clinical Characteristics of COVID-19 Patients With Pancreatic Injury
| Variable, n (%) or median (IQR) | Normal range | Nonsevere (n = 1) | Severe (n = 12) |
|---|---|---|---|
| Age, y | – | 44 | 62 (53–69) |
| Male | – | N | 6 (50.0%) |
| BMI | 20–25 | 28.4 | 27.2 (24.5–28.7) |
| Incubation period, d | 2–7 | 4 | 4 (3–7) |
| Comorbidities | |||
| Hypertension | – | N | 5 (41.7%) |
| Diabetes | – | Y | 5 (41.7%) |
| CHD | – | N | 1 (8.3%) |
| Presenting symptoms | |||
| Fever | – | Y | 7 (58.3%) |
| Short of breath | – | N | 8 (66.7%) |
| Cough | – | N | 4 (33.3%) |
| Fatigue | – | N | 4 (33.3%) |
| Diarrhea | – | N | 2 (16.7%) |
| Headache | – | N | 2 (16.7%) |
| Complications | |||
| ARDS | – | N | 6 (50.0%) |
| Cardiac injury | – | N | 2 (16.7%) |
| Kidney injury | – | N | 4 (33.3%) |
| Liver injury | – | Y | 7 (58.3%) |
| Shock | – | N | 4 (33.3%) |
| NSAIDs used | – | N | 2 (16.7%) |
| Laboratory findings on admission | |||
| WBC, ×109/L | 3.5–9.5 | 5.62 | 4.56 (3.80–10.20) |
| Lymphocyte count, ×109/L | 1.10–3.20 | 0.89 | 0.66 (0.43–0.92) |
| Neutrophil count , ×109/L | 1.80–6.30 | 4.13 | 5.02 (2.27–7.20) |
| Platelet count, ×109/L | 125.0–350.0 | 227 | 156 (145–280) |
| Hemoglobin, g/L | 130–175 | 127 | 125 (121–150) |
| ALT, U/L | 7.0–40.0 | 45 | 31 (20–78) |
| AST, U/L | 13.0–35.0 | 37 | 34 (31–51) |
| T-BIL, μmol/L | 0–21.0 | 10.9 | 11.4 (9.8–14.4) |
| Albumin, g/L | 40.0–55.0 | 48.5 | 36.0 (32.5–40.0) |
| Creatinine, μmol/L | 41.0–73.0 | 38 | 56 (42–69) |
| BUN, mmol/L | 2.6–7.5 | 3.2 | 6.0 (4.4–7.2) |
| Amylase, U/L | 35–135 | 76 | 62 (59–121) |
| >135 U/L | – | N | 3 (25.0%) |
| Lipase, U/L | 8–78 | 56 | 31 (24-48) |
| >78 U/L | – | N | 3 (25.0%) |
| PT, s | 11.5–14.5 | 12.5 | 12.5 (12.0–14.0) |
| APTT, s | 29.0–42.0 | 37.5 | 35.6 (34.5–39.8) |
| INR | 0.8–1.2 | 1.1 | 1.0 (0.9–1.0) |
| D-dimer, mg/L | 0–1.5 | 0.2 | 0.1 (0.1–1.12) |
| PCT, ng/mL | 0.02–0.05 | 0.04 | 0.32 (0.08–0.49) |
| CRP, mg/L | 0–5.0 | 16 | 27.8 (18.8–86.0) |
| Ferritin, ng/mL | 4.63–204 | 675 | 998 (701–1160) |
| Increased AMS/LPS after admission | |||
| Amylase, U/L | 35–135 | 175 | 213 (186–277) |
| >135 U/L | – | Y | 12 (100%) |
| Lipase, U/L | 8–78 | 102 | 156 (104–228) |
| >78 U/L | – | Y | 11 (91.7%) |
| Treatments | |||
| Oxygen support | – | N | 12 (100%) |
| Mechanical ventilation | – | N | 7 (58.3%) |
| Antiviral treatment | – | N | 9 (75.0%) |
| Antimicrobial treatment | – | N | 10 (83.3%) |
| Glucocorticoids | – | N | 4 (33.3%) |
| ICU admission | – | N | 6 (50.0%) |
| Outcome | |||
| Discharge | – | Y | 7 (58.3%) |
| Dead | – | - | 5 (41.7%) |
ALT, alanine aminotransferase; AMS, amylase; APTT, activated partial thromboplastin time; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen, CHD, coronary heart disease; CRP, C-reactive protein, ICU, intensive care unit; INR, international standard ratio, LPS, lipase; NSAIDs, nonsteroidal anti-inflammatory drugs; PCT, procalcitonin, PT, prothrombin time; T-BIL, total bilirubin; WBC, white blood cells.